AgPlenus Announces Significant Progress in Its Fungicide Discovery Programs Targeting New Modes of Action, with Activity Against Resistant Septoria and Additional Fungal Pathogens
Source: PR NewswireView original on PR Newswire
Active molecules generated by ChemPass AI for Ag, demonstrate promising fungicidal activity, including against fungicide-resistant Septoria strains
REHOVOT, Israel, Nov. 17, 2026 /PRNewswire/ -- AgPlenus Ltd., a developer of novel crop-protection products and a subsidiary of Evogene Ltd. (Nasdaq: EVGN), today announced significant progress in two fungicide discovery programs targeting novel modes of action against Septoria tritici blotch (STB), one of the most economically significant diseases affecting global wheat production.


Caused by Zymoseptoria tritici, STB is a major cause of wheat yield losses worldwide. Historically, more than 70% of fungicide use in European wheat production has been directed at STB, representing an estimated market opportunity of approximately €1.2 billion[1]. Growing resistance to widely used fungicides, including succinate dehydrogenase inhibitors (SDHIs), further underscores the need for new modes of action[2] .
AgPlenus is addressing this challenge by targeting previously untapped proteins essential for fungal survival. Leveraging its ChemPass AI for Ag™ discovery platform, the company identified active small molecules across both programs, that inhibited their intended fungal targets and showed promising fungicidal activity, including against fungicide-resistant Septoria strains. Selected compounds also reduce disease by 75% in plan tissue assays. Importantly, selected biological findings have been independently corroborated by an external research organization, providing additional validation of the observed activity and supporting the continued advancement of both programs.
Beyond Septoria, selected compounds have demonstrated activity against additional fungal pathogens, pointing to potential applications across a broader range of crop diseases. These findings provide a foundation for further molecular optimization, expanded biological evaluation, and the potential development of differentiated fungicide candidates.
The advancements highlight the capabilities of ChemPass AI for Ag™, AgPlenus' integrated discovery and optimization platform combining AI-driven molecular design, predictive biology, and proprietary chemistry expertise. By integrating computational predictions with experimental validation, the platform enables the identification and optimization of novel molecules against previously untapped fungal targets, creating opportunities to the development of differentiated crop-protection solutions.
Orli Even Or, PhD. VP R&D of AgPlenus, commented: "The growing challenge of fungicide resistance highlights the urgent need for new modes of action in crop protection. Making progress in two independent fungicide discovery programs, with compounds demonstrating activity against resistant Septoria strains and additional fungal pathogens, represents an important milestone for AgPlenus. These results demonstrate the potential of our AI-driven discovery platform to translate novel biological insights into differentiated fungicide candidates and address broader crop-protection needs."
About AgPlenus Ltd.
AgPlenus, a subsidiary of Evogene Ltd., is an AI-driven crop protection discovery company focused on developing effective and sustainable solutions to address the growing challenge of pesticide resistance. The company leverages ChemPass AI for Ag™, a technology platform licensed from Evogene, integrating predictive biology, artificial intelligence, and computational chemistry to discover novel crop-protection molecules. Through its target-based discovery approach, AgPlenus aims to improve discovery efficiency, reduce development risks, and advance differentiated crop-protection solutions with the potential to address unmet agricultural needs.
For more information, please visit www.agplenus.com
About Evogene Ltd.
Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company in computational chemistry specializing in the generative design of small molecules for drug development and ag-chemical products. At the core of its technology is ChemPass AI™ a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.
For more information, please visit www.evogene.com
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to future events. These statements may be identified by words such as "may," "could," "expects," "hopes," "intends," "anticipates," "plans," "believes," "scheduled," "estimates," "demonstrates", "designed to," "intended to," "with the goal of," or words of similar meaning. For example, Evogene and its subsidiaries use forward-looking statements in this press release when it discusses: the potential applications across a broader range of crop diseases beyond septoria treatment. The potential development of differentiated fungicide candidates. The estimated market opportunity of Septoria treatment. The creation of opportunities for the development of differentiated crop-protection solutions. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the aftermath of the recent war between Israel and each of (i) the terrorist groups, Hamas and Hezbollah, (ii) Iran, and (iii) other regional terrorist groups supported by Iran, and any potential destabilizations in Israel, neighboring territories or the Middle East region, and those risk factors contained in Evogene's reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Investor Relations Contact:
[email protected]
Tel: +972-8-9311901
[1] Hehir et al. (2018). Plant Pathology, 67, 573–583. DOI
[2] Andresen et al. (2026). European Journal of Plant Pathology. DOI
View original content to download multimedia:https://www.prnewswire.com/news-releases/agplenus-announces-significant-progress-in-its-fungicide-discovery-programs-targeting-new-modes-of-action-with-activity-against-resistant-septoria-and-additional-fungal-pathogens-302941919.html
Source: PR NewswireView original on PR Newswire
Content provided by PR Newswire. Redistribution, resale or sublicensing is not permitted.